Lipella Pharmaceuticals Inc.
Lipella - LP-10 (Liposomal Tacrolimus) for the Treatment of Hemorrhagic Cystitis
Hemorrhagic Cystitis, also called Radiation Cystitis when occurring after pelvic radiation. Lipella is currently conducting a phase-2a, dose-escalation clinical trial evaluating LP-10 (liposomal tacrolimus) for the treatment of hemorrhagic cystitis. Lipella has received US-FDA Orphan Designation for this developmental product. Radiation used to treat prostate, colon, uterine, cervical and other pelvic cancers can cause chronic, painful urinary inflammation and blood loss called hemorrhagic cystitis. The blood loss, associated with hemorrhagic cystitis and radiation cystitis can lead to surgery, and can be fatal.
Most popular related searches
blood loss
drug treatment
chronic pain
urinary incontinence
clinical trial
radiotherapy
colon
prostate
pain inflammation
drug approval
- There are approximately one million cancer survivors in the U.S. that have received pelvic radiation therapy for malignancies of the prostate, uterine, cervix, or colon.
- Hemorrhagic cystitis and radiation cystitis are associated with significant morbidity and mortality and yet there are currently no FDA approved drug treatment.
- Hemorrhagic cystitis and radiation cystitis patients suffer highly debilitating symptoms including blood in the urine that can lead to clotting, pain in the bladder, and urinary incontinence.